Knowledge about the molecular aberrations driving the development and progression of primary central nervous system tumors is steadily increasing, including recent discoveries of novel genetic aberrations in both pediatric and adult brain tumors, such as the frequent mutations in the isocitrate dehydrogenase 1 (IDH1) gene in diffuse gliomas or the aberrant activation of BRAF signaling in pilocytic astrocytomas. Importantly, evidence is accumulating that certain molecular changes are closely associated with therapy response and/or patient survival, thus making them attractive targets for molecular diagnostic testing aiming to improve treatment stratification and prognostic assessment of the individual patient. Prominent examples of molecular markers that have elicited substantial clinical interest are the association of MGMT promoter methylation with sensitivity to alkylating chemotherapy and longer survival in glioblastoma patients as well as the combined complete loss of chromosomal arms 1p and 19q as a powerful prognostic marker in patients with (oligodendro)glial tumors. Furthermore, assessment of the mutation status of IDH1, either by immunohistochemistry or by DNA sequencing, has been identified as a powerful diagnostic and prognostic marker in diffuse gliomas, while the detection of BRAF aberrations may facilitate the diagnosis of pilocytic astrocytomas [1] .
Similarly, recent studies on embryonal central nervous system (CNS) tumors have shown that medulloblastomas can be molecularly subdivided into pathogenetically distinct subgroups based on mRNA profiles indicative of aberrant activation of different signaling pathways, such as the sonic hedgehog or wingless signaling cascades. Furthermore, several genetic and chromosomal markers have been identified that are closely linked to the survival of medulloblastoma patients, most notably amplification of MYC and MYCN, mutation/nuclear accumulation of bcatenin, copy number changes of chromosome 6, and aberrations of chromosome 17. Combined assessment of these markers allows for a greatly improved risk stratification of medulloblastoma patients that will likely be implemented into upcoming clinical trials. Moreover, characteristic molecular alterations have been identified for certain less common embryonal tumor entities, including mutation and loss of expression of SMARCB1 (INI1/ hSNF5) in atypical teratoid/rhabdoid tumors as well as focal amplification of a micro-RNA cluster at chromosome 19q13.42 in ependymoblastoma/embryonal tumor with abundant neuropil and true rosettes, respectively [2] .
Traditionally, the classification and grading of brain tumors is based on the assessment of histopathological and immunohistochemical features under the light microscope according to the criteria defined in the World Health Organization (WHO) classification of tumors of the central nervous system. This morphological analysis, however, tells only 'part of the story' of a tumor. There is no problem as long as the information generated by the educated analysis of a histological slide (which is in fact a 'systematic artifact' created by fixation, further tissue processing, cutting and staining of tumor tissue) leads to a highly reproducible diagnosis that conveys the information required for the assessment of prognosis and therapeutic decision-making. However, the WHO criteria for typing and grading of tumors are not always precise, and it is far from easy to substantially improve this situation, mainly because of the 'nature of the game', that is the biological variation that is difficult to capture in strict criteria and predefined boxes, such as the WHO grades. Unfortunately, this situation causes substantial interobserver variation in the classification of, e.g., diffuse gliomas, even among experienced neuropathologists, and may well have undesirable clinical consequences. Moreover, tissue sampling is often incomplete, which for example may lead to underestimation of the true malignancy in regionally heterogeneous tumors. In addition, novel therapeutic modalities are available now that require specific information about a tumors pathobiology. Often, this kind of information cannot be assessed by morphology or immunohistochemistry, examples being the presence or absence of certain gene mutations and epigenetic DNA modifications. Therefore, molecular diagnostics nowadays already plays an important role in the daily diagnostic practice of various cancers outside the nervous system, e.g., sarcomas, lymphomas and certain types of carcinomas.
The review articles clustered in this edition of Acta Neuropathologica are meant to give an update on the state of the art of molecular diagnostics for the two main categories of CNS tumors in which recent developments in this respect are most striking, that is the gliomas [1] and the embryonal CNS tumors [2] . Brain tumor diagnostics and therapy nowadays is a multidisciplinary task that requires close collaboration of colleagues from neurosurgery, radiation oncology, pediatric and medical oncology, neuroradiology, neuropathology and others. Each specialty may have slightly distinct views and demands concerning brain tumor diagnostics. Therefore, we additionally asked distinguished colleagues from neurooncology and neurosurgery to review the issue of molecular diagnostics of gliomas from a clinician's point of view, with a particular focus on the role of molecular diagnostics in ongoing and upcoming clinical trials [3] .
It is important to realize that the developments in molecular neurooncology are rapidly evolving. Novel techniques employing next generation sequencing approaches are presently used in international consortia for the systematic, genome-wide detection of mutations in cancer [4] . These efforts will provide a plethora of new genetic information linked to various types of cancer including brain tumors. This means that our current, still rather limited knowledge on the genes and pathways involved in the oncogenesis of particular brain tumors will greatly expand in the near future. Hopefully, this will reveal novel clinically useful markers and pave the way to the development of more effective drugs specifically targeting such pathways, thereby providing better opportunities for individualized therapies.
Concerning neuropathology, these developments can be looked at as a threat in terms of possibly reducing the role of classic, morphology-based histopathology, but also as a great opportunity. We strongly advocate the latter point of view and feel that we live in an exciting era, the challenge in this respect being to combine the classic morphological approach (which undoubtedly will remain an important basis for brain tumor diagnostics) with molecular diagnostics in a smart way that provides the best possible information for the individual patient. The result of this combined approach may well be that parts of the morphological system for typing and grading of brain tumors will become less relevant and possibly overruled by certain molecular findings. However, this needs to be thoroughly evaluated in future clinical trials, followed by rigorous validation in the daily routine practice. There is a fair chance that, after enthusiastic introduction of particular markers, reality checks will teach us later on that the information provided by certain markers is not as robust/ straightforward as it was originally expected or hoped for.
The application of molecular tests in the diagnostic assessment of brain tumors has a number of immediate implications for surgical neuropathology that need to be dealt with. As these tests are performed on tumor tissue specimens, we would strongly argue that not only the morphological but also the molecular diagnostic tests should be performed or at least be supervised by the responsible (neuro)pathologist. In fact, parameters like tissue quality and quantity are of utmost importance also for molecular diagnostics and the (neuro)pathologist plays a key role as tissue professional in the assessment and selection of the material that is used for subsequent molecular testing. Moreover, the interpretation of molecular results usually only makes sense when intimately linked to the histological classification. However, this implies that (neuro)pathologists receive adequate training not only in morphological but also in molecular methods as well as in the critical interpretation of molecular results. In case that more sophisticated techniques are required, assistance by colleagues with a profound background in molecular biology may be needed. However, it is also possible that such assays will become part of a routine palette of procedures that can be technically carried out by a technician rather than a molecular biologist (as they are, e.g., well established for immunohistochemistry), and that the modern neuropathologist functions as an integrator of the morphological and molecular information in a clinically relevant way. No matter how this combined morphological and molecular approach will be organized, when applying such methods it is extremely important to realize that molecular tests are associated with a number of inherent pitfalls and methodological limitations. Molecular tests may provide misleading results when improperly applied or wrongly interpreted. Moreover, molecular tests do not shield from inter-observer variability, as the use of different techniques and thresholds in different laboratories may result in distinct, sometimes even contradictory results. This is particular evident for the assessment of epigenetic markers, such as MGMT promoter methylation, which may be performed by a variety of different assays targeting variable parts of the MGMT-associated 5 0 -CpG island [1] . Thus, it will be important to devise standardized test assays and establish appropriated measures of quality control, in which (neuro)pathologists applying molecular diagnostic tests need to participate to allow for comparison of results obtained in different institutions. Finally, the implementation of molecular diagnostics as part of the routine armamentarium for brain tumor classification also requires acknowledgement of these tests in terms of appropriate financial reimbursement within the respective health systems.
In summary, the review cluster in this issue provides the current state of the art of molecular diagnostics for gliomas and embryonal CNS tumors. For both of these tumor categories tremendous advances have been made in the last couple of years with several new molecular markers being translated into clinical application. However, there still remains a lot to be learned about the clinical relevance of existing markers as well as about how to analyze and utilize these markers in daily clinical practice for optimal benefit of the individual patient with a brain tumor. Moreover, it is to be expected that the number of informative molecular markers in brain tumor diagnostics will steadily increase. Thus, these are exciting times for those involved in brain tumor diagnostics, especially for the (neuro)pathologist as an integrator of the morphological and molecular information that can be extracted from the tumor tissue. We'd better be prepared!
